Anat Ashkenazi

Anat Ashkenazi became CFO of Alphabet, the parent company of Google, in July 2024. One of her strategic priorities as finance chief of the nearly $2 trillion company is to integrate AI within its processes to boost efficiency and productivity, with cost reductions helping to fund AI innovation. Ashkenazi will oversee Alphabet’s investment of approximately $75 billion in capital expenditures in 2025, with a significant portion of this spending dedicated to AI infrastructure. Ashkenazi previously had a 23-year career at Eli Lilly and Company, culminating in her appointment as CFO in 2021. Ashkenazi supported the development of groundbreaking weight loss drugs Zepbound and Mounjaro.